Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 10/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 10/20 | 0.50 |
| ▸ | CHRNB4 | P30926 | 7/20 | 0.50 |
| ▸ | CHRNA3 | P32297 | 7/20 | 0.50 |
| ▸ | LCAT | P04180 | 3/20 | 0.47 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16648709 | 0.84 | PARP1 (0.44) | LCATUSP30 | |
| SCHEMBL16648729 | 0.83 | DRD2 (0.52) | LCATUSP30 | |
| SCHEMBL16648768 | 0.79 | LCAT (0.49) | CHRNB4CHRNA3LCATPIM1 | |
| SCHEMBL16648536 | 0.79 | CHRNB2 (0.51) | CHRNB2CHRNA4CHRNB4CHRNA3LCAT | |
| SCHEMBL16648963 | 0.78 | LCAT (0.50) | CHRNB2CHRNA4CHRNB4CHRNA3LCAT | |
| SCHEMBL16648757 | 0.78 | LCAT (0.46) | CHRNB2CHRNA4CHRNB4CHRNA3LCAT | |
| SCHEMBL16664264 | 0.78 | LCAT (0.46) | LCATDPP4DPP8DPP9DPP7 | |
| SCHEMBL16648666 | 0.77 | CHRNB2 (0.46) | CHRNB2CHRNA4CHRNB4CHRNA3LCAT | |
| SCHEMBL649095 | 0.76 | CHRNB2 (0.58) | CHRNB2CHRNA4CHRNB4CHRNA3LCAT | |
| SCHEMBL16648971 | 0.75 | LCAT (0.48) | LCATDPP4CHRM4USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2862861-B1 | PIPERIDINYLPYRAZOLOPYRIDINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2016-01-06 | — | — | EP | disclosed |
| EP-2862861-B1 | PIPERIDINYLPYRAZOLOPYRIDINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2016-01-06 | — | — | EP | disclosed |
| US-9150575-B2 | Piperidinylpyrazolopyridine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-10-06 | — | — | US | disclosed |
| US-9150575-B2 | Piperidinylpyrazolopyridine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-10-06 | — | — | US | disclosed |
| CN-104781257-A | Piperidinylpyrazolopyridine derivative | DAIICHI SANKYO CO LTD | 2015-07-15 | — | — | CN | disclosed |
| US-20150152102-A1 | PIPERIDINYLPYRAZOLOPYRIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-06-04 | — | — | US | disclosed |
| US-20150152102-A1 | PIPERIDINYLPYRAZOLOPYRIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-06-04 | — | — | US | disclosed |
| EP-2862861-A1 | PIPERIDINYLPYRAZOLOPYRIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-04-22 | — | — | EP | disclosed |
| EP-2862861-A1 | PIPERIDINYLPYRAZOLOPYRIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152102-A1 | PIPERIDINYLPYRAZOLOPYRIDINE DERIVATIVE | LCAT, LPL, LCLAT1 | CHRNB2 3937/4885CHRNA4 3753/4885CHRNB4 4086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.